Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Defends Its Offensive Strategy For Keytruda

Jul 30 2016

• By Emily Hayes

White cells

Related Content

Medicaid May Offer Best Opportunity For Merck’s Zepatier

Mar 28 2016

Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Jun 16 2016

Gilead Sees Prospects For Declining HCV Revenues To Stabilize

Jul 28 2016

Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks

Jul 29 2016

Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing

May 31 2016

Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch

May 13 2016

Merck Is Finding PD-L1 Testing Is Helping Keytruda

May 06 2016

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Gilead Sciences, Inc.

Additional Topics

Business Strategies Commercial Companies Cancer BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window